Home Newsfeeds Chardan Capital Reiterates Buy on PLBY Group, Maintains $5 Price Target

Chardan Capital Reiterates Buy on PLBY Group, Maintains $5 Price Target

Chardan Capital analyst Brian Dobson reiterates PLBY Group (NASDAQ:PLBY) with a Buy and maintains $5 price target.

byBenzinga Newsdesk

February 13, 2023

1 minute read

Chardan Capital analyst Brian Dobson reiterates PLBY Group (NASDAQ:PLBY) with a Buy and maintains $5 price target.

JP Morgan Maintains Neutral on DISH Network, Lowers Price Target to $18

By Benzinga Newsdesk

February 27, 10:04 AM

JP Morgan analyst Philip Cusick maintains DISH Network (NASDAQ:DISH) with a Neutral and lowers the price target from $24 to $18.

DISH

What’s Going On With SunPower Stock After Hours?

By Adam Eckert

February 15, 6:35 PM

SunPower Corp (NASDAQ: SPWR) shares are rising after hours following the company's fourth-quarter results, which exceeded analyst expectations.

PACCAR Increases Regular Quarterly Dividend From $0.25 To $0.27/Share

By Benzinga Newsdesk

July 11, 10:31 AM

PACCAR Inc's Board of Directors today approved an increase of 8% in the regular quarterly cash dividend from twenty-five cents ($.25) per share to twenty-seven cents ($.27) per share. The dividend will be payable on September 7, 2023, to stockholders of record at the close of business on August 17, 2023.

PCAR

Bristol Myers Squibb Announces KRAZATI In Combination With Cetuximab Demonstrates Clinically Meaningful Activity As A Targeted Treatment Option For Patients With Previously Treated KRAS G12C-Mutated Locally Advanced Or Metastatic Colorectal Cancer

By Benzinga Newsdesk

April 8, 11:31 AM

Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press programBristol

BMY

Chardan Capital Reiterates Buy on PLBY Group, Maintains $5 Price Target

Related Posts

JP Morgan Maintains Neutral on DISH Network, Lowers Price Target to $18

What’s Going On With SunPower Stock After Hours?

PACCAR Increases Regular Quarterly Dividend From $0.25 To $0.27/Share

Bristol Myers Squibb Announces KRAZATI In Combination With Cetuximab Demonstrates Clinically Meaningful Activity As A Targeted Treatment Option For Patients With Previously Treated KRAS G12C-Mutated Locally Advanced Or Metastatic Colorectal Cancer